October 20, 2015

RXi Pharmaceuticals announces remarkable and positive results with its Novel Self-Delivering RNAi Platform: Potent Reduction of Long Non-coding RNAs Demonstrated in Collaboration with Biogazelle

MARLBOROUGH, Mass., Oct. 20, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced positive results from a collaboration with Biogazelle NV.  Biogazelle is a company with a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs (lncRNA). 

October 15, 2015

Biogazelle and Ionis Pharmaceuticals evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part of this collaboration, Isis will provide access to its proprietary antisense platform to Biogazelle for large-scale validation of therapeutic long non-coding RNA (lncRNA) targets from Biogazelle’s proprietary target identification pipeline.

August 12, 2015

Biogazelle receives €1.1M IWT funding to develop lncRNA targeting cancer therapies

Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focused on silencing long non-coding RNAs (lncRNAs). Last year, Biogazelle initiated the development of lncRNA-targeting therapies in colon, liver and lung cancer.

June 12, 2015

Biogazelle offers unique microRNA sequencing on challenging samples

Biogazelle has a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs. Today, the service portfolio is extended with a unique offering, namely the use of massively parallel sequencing to quantify microRNAs in compromised samples characterized by degraded RNA or low output amounts of RNA.